171 related articles for article (PubMed ID: 37229919)
21. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Heinze K; Cairns ES; Thornton S; Harris B; Milne K; Grube M; Meyer C; Karnezis AN; Fereday S; Garsed DW; Leung SCY; Chiu DS; Moubarak M; Harter P; Heitz F; McAlpine JN; DeFazio A; Bowtell DDL; Goode EL; Pike M; Ramus SJ; Pearce CL; Staebler A; Köbel M; Kommoss S; Talhouk A; Nelson BH; Anglesio MS
Clin Cancer Res; 2023 Sep; 29(17):3471-3483. PubMed ID: 37339172
[TBL] [Abstract][Full Text] [Related]
22. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
[TBL] [Abstract][Full Text] [Related]
23. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
25. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
26. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
[TBL] [Abstract][Full Text] [Related]
27. [Molecular classification of endometrial carcinoma-a short summary for clinical use].
Hiller GGR; Höhn AK; Mayr D; Brambs CE; Horn LC
Pathologie (Heidelb); 2023 Nov; 44(6):392-400. PubMed ID: 37815668
[TBL] [Abstract][Full Text] [Related]
28. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
29. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
[TBL] [Abstract][Full Text] [Related]
31. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract][Full Text] [Related]
32. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
33. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
34. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
Wu Q; Zhang N; Xie X
BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
[TBL] [Abstract][Full Text] [Related]
35. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
36. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
38. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
39. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
